Medline (NASDAQ:MDLN) Stock Rating Upgraded by Wall Street Zen

Key Points

• Wall Street Zen upgraded Medline from “hold” to “buy.” Overall, 23 analysts rate the stock Buy, four Hold and two Sell, with a consensus “Moderate Buy” rating and a $46.08 price target.
• Medline reported quarterly EPS of $0.44, beating the $0.32 consensus, and revenue of $7.86 billion.
• Insiders sold nearly 7.95 million shares worth about $281.8 million over the past 90 days; corporate insiders own 0.81% of the stock.

Medline (NASDAQ:MDLN - Get Free Report) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research report issued on Saturday, Wall Street Zen reports.

Other research analysts have also recently issued research reports about the stock. Barclays dropped their price objective on shares of Medline from $45.00 to $43.00 and set an "overweight" rating for the company in a report on Friday, October 9th. Tigress Financial lowered their target price on Medline from $62.00 to $55.00 and set a "buy" rating on the stock in a research report on Tuesday, August 11th. Leerink Partners upped their target price on shares of Medline from $43.00 to $46.00 and gave the stock an "outperform" rating in a research note on Thursday. UBS Group raised their price objective on shares of Medline from $43.00 to $49.00 and gave the company a "buy" rating in a research note on Thursday. Finally, Citigroup raised their price objective on Medline from $45.00 to $47.00 and gave the stock a "buy" rating in a research note on Thursday. Twenty-three analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Medline currently has a consensus rating of "Moderate Buy" and a consensus price target of $46.08.

Medline Stock Down 0.3%

Shares of NASDAQ:MDLN opened at $39.64 on Friday. The firm has a market capitalization of $52.12 billion and a PE ratio of 90.09. The company has a debt-to-equity ratio of 0.66, a current ratio of 4.33 and a quick ratio of 2.61. Medline has a 1 year low of $31.37 and a 1 year high of $50.88. The firm's 50-day moving average is $34.78 and its two-hundred day moving average is $39.48.

Medline (NASDAQ:MDLN - Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.32 by $0.12. The company had revenue of $7.86 billion during the quarter. Analysts predict that Medline will post 1.49 EPS for the current year.

Insider Buying and Selling

In other Medline news, major shareholder Private Ltd Gic sold 2,088,987 shares of the business's stock in a transaction that occurred on Tuesday, October 6th. The stock was sold at an average price of $35.05, for a total transaction of $73,218,994.35. Following the transaction, the insider owned 16,453,806 shares in the company, valued at approximately $576,705,900.30. The trade was a 11.27% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders sold a total of 7,948,676 shares of company stock valued at $281,805,137 in the last 90 days. 0.81% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Medline

Several institutional investors have recently modified their holdings of MDLN. Mass General Brigham Inc raised its position in Medline by 167.6% in the 1st quarter. Mass General Brigham Inc now owns 70,357 shares of the company's stock valued at $3,131,000 after buying an additional 44,063 shares during the last quarter. Andra AP fonden purchased a new position in shares of Medline during the 2nd quarter worth $3,180,000. Cetera Investment Advisers grew its position in Medline by 128.4% during the 1st quarter. Cetera Investment Advisers now owns 52,088 shares of the company's stock worth $2,318,000 after purchasing an additional 29,282 shares during the last quarter. Baird Financial Group Inc. grew its stake in Medline by 1,151.5% in the 2nd quarter. Baird Financial Group Inc. now owns 379,944 shares of the company's stock worth $14,985,000 after acquiring an additional 349,584 shares during the period. Finally, WINTON GROUP Ltd raised its holdings in shares of Medline by 1,263.0% during the second quarter. WINTON GROUP Ltd now owns 367,057 shares of the company's stock worth $14,477,000 after purchasing an additional 340,127 shares during the period.

Key Stories Impacting Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Medline reported Q3 EPS of $0.44, beating the $0.32 consensus estimate, with revenue of $7.86 billion. Shares gapped higher following the earnings report. Medline shares gap up following strong earnings
• Positive Sentiment: Analyst target increases add to the bullish outlook: UBS raised its target to $49 and maintained a Buy rating; Citi raised its target to $47 and kept Buy; and Leerink Partners lifted its target to $46 with an Outperform rating. UBS ratings Citi ratings Leerink Partners ratings
• Positive Sentiment: BTIG reaffirmed its Buy rating with a $55 target, while Barclays also assigned a Buy rating, adding to the favorable analyst sentiment. BTIG ratings Barclays rating
• Positive Sentiment: Medline plans price increases in 2027 to offset inflation, which could help protect revenue and profitability if customers accept the higher prices. Pricing plans and Q3 results

Medline Company Profile

Medline is a healthcare products manufacturer and distributor serving providers across the care continuum. Its customers include hospitals, surgery centers, physician practices, long-term care facilities and home-care organizations.

The company offers a broad range of medical and surgical supplies, including products for infection prevention, wound care and patient care, as well as apparel and equipment. Medline also provides supply-chain and logistics services to healthcare organizations.

Founded in 1966, Medline is headquartered in Northfield, Illinois, and serves customers in the United States and internationally.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.